

## Special Issue

# Personalized Diagnosis and Treatment for Congenital Heart Disease

### Message from the Guest Editors

Patients with congenital heart disease are surviving into adulthood thanks to advances in diagnosis as well as therapy at an early age. In fact, there are more adults with congenital heart disease than children, with an ever-growing population. Educating and empowering patients as well as their primary care providers and general cardiologists are important for optimizing the patients' longitudinal care. Moreover, recognizing that the interventions patients have undergone, whether surgical or percutaneous, are palliative means that, in most cases, these patients would require lifelong follow-up at a center with adult congenital heart disease expertise. Common long-term issues, depending on the cardiac abnormalities, can include a need for re-intervention, heart failure, arrhythmias, pulmonary hypertension, endocarditis, risk of thromboembolism, and risk with pregnancy/risk to offspring. However, although the guidelines provide general principles of care, each patient may demonstrate unique features of their cardiac abnormalities and their care must be individualized.

---

### Guest Editors

Dr. David S. Majdalany

Department of Cardiovascular Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA

Dr. Donald J. Hagler

1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA

2. Division of Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA

---

### Deadline for manuscript submissions

20 December 2024



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/176691](https://mdpi.com/si/176691)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm.mdpi.com)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).